Materialise (MTLS) has released an update.
Materialise reported a 14.2% increase in revenue for Q3 2024, driven by strong growth in its Medical segment, despite a decline in net profit due to unfavorable currency exchange effects. The company’s operating result improved significantly, reflecting robust performance across its business units. Materialise’s cash position remains stable, and its adjusted EBITDA saw notable growth, highlighting its potential for sustained financial health.
For further insights into MTLS stock, check out TipRanks’ Stock Analysis page.
